Sydney’s biotech industry includes national and local companies, startups and multinational enterprise firms. These organizations focus on treatments for acute and chronic diseases and conditions, as well as on products that integrate healthcare and industry. Here are the ones to know.
Biotech Companies in Sydney
- GLIA Diagnostics
- Roche
- NanoMed
- CSL
- Biogen
Top Biotech Companies in Sydney
GLIA Diagnostics researches and develops biotech solutions for traumatic brain injury, concussion and PTSD. Using clinical trials to identify biomarkers of these conditions, its technology’s goal is to create a way to definitively diagnose them. GLIA was founded in reaction to the limitations of the standard siloed approach to medical research.
Roche is a multinational biotech and pharmaceutical firm, best known as the creator of Valium. Its work in biotech focuses on research and development in treatments and diagnostics, including molecular diagnostics to identify biomarkers of certain conditions and blood glucose management systems for diabetes. Roche also owns several independently operated biotech companies.
NanoMed is a nanobiotechnology company, which takes the material principles and techniques of nanoscale, or ultra tiny, biology and applies them to biosystems. NanoMed is focused on the development of diagnostic imaging agents and cancer therapeutics, using lipid-based nanomedicines. Because the scale of nanomedicine is so small, it can subvert the standard risk-to-reward ratio of cancer treatment, in which researchers aim to balance efficacy against toxicity.
CSL makes biotherapeutics for bleeding disorders, immunodeficiency, cardiovascular disease and kidney disease. Its product line includes vaccines, antivenom and blood plasma derivatives, which are used in genetic and medical research. Founded in 1916 as an entity of the Australian government devoted to vaccine research and manufacture, the company privatized in 1994.
Biogen is a biotech firm that works on therapies for neurological diseases and other serious conditions, including Alzheimer’s, multiple sclerosis, lupus, spinal muscular atrophy and postpartum depression. Biogen is invested in the creation of biosimilars as a public good, which are cost-saving alternatives to patented name brand drugs. These are different from generics in that they are biologically slightly different than the patented treatments, yet work identically.
